SOHO State of the Art Updates and Next Questions | Current and Emerging Novel Treatments for Marginal Zone Lymphoma.

Izidore S Lossos

Abstract readReview

In one paragraph

Review in Clinical lymphoma, myeloma & leukemia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Izidore S LossosDivision of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; Department of Molecular and Cellular Pharmacology, University of Miami, Miami, FL. Electronic address: ilossos@med.miami.edu.

Funding

Tumor Biology Research ProgramP30CA240139 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Stephen D. Nimer · 2019 to 2026

$24.1M

Identify the Mechanisms of LMO2-Mediated Inhibition of Homologous Recombination and Establish PARP-Targeted Synthetic Lethality as a New Therapy for DLBCLR01CA233945 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI LOSSOS, IZIDORE S, VERDUN, RAMIRO ERNESTO · 2019 to 2023

$1.8M

NCI NIH HHS P30 CA240139NCI NIH HHS R01 CA233945

6 · The paper itself

Abstract

Marginal zone lymphoma (MZL) is a heterogeneous disease representing 7% to 10% of non-Hodgkin lymphomas (NHL). There are no clear guidelines defining the need for treatment initiation and no standardized therapeutic approach for patients with MZL. Previously, many treatments were extrapolated from clinical trials that mainly enrolled patients with follicular lymphoma and did not have statistical power to show treatment efficacy specifically in MZL patients. Currently, the field is moving toward conducting specific trials in MZL patients with specific inclusion criteria for each MZL subtype, assessing response distinctively in FDG avid and nonavid MZL tumors and using MZL-relevant primary endpoints. Herein I briefly describe these changes, summarize previous therapeutic studies in MZL and present preliminary publicly available data on novel emerging treatments, including bispecific antibodies, antibody drug conjugates and novel targeted therapies.

Indexed as

Lymphoma, B-Cell, Marginal ZoneHumansMolecular Targeted TherapyBispecific antibodiesBruton tyrosine kinase (BTK) inhibitorsExtranodal marginal zone lymphoma (EMZL)Nodal marginal zone lymphoma (NMZL)Splenic marginal zone lymphoma (SMZL)

Identifiers

PMID40581510

DOI10.1016/j.clml.2025.05.021

PMCPMC12354275

What Socratic holds

Textmetadata

LicenceTDM

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.